Lilly Asia Ventures
Lilian Wan is a Vice President with Lilly Asia Ventures. Previously, Lilian was an Associate Director at HSBC Global Asset Management. Prior to that, Lilian served as the lead analyst in healthcare with BOCOM International, Equity Research Associate with BofA Merrill Lynch, Jefferies and CICC. Lilian holds a M.P.H degree from Harvard T.H. Chan School of Public Health, a Master's Degree in Economics from Peking University and a Bachelor's Degree in Biotechnology from Nanjing university.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.